Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Design Therapeutics, Inc.
Market Cap
$736.99M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$755.18M
Net Profit Margin
-4490.89%
TTM Avg
-2245.45%
3Y Avg
-2245.45%
5Y Avg
-2245.45%
Market Cap
$724.64M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-3758.80%
5Y Avg
-9679.73%
Market Cap
$721.40M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$761.35M
Net Profit Margin
1.92%
TTM Avg
0.94%
3Y Avg
-28.83%
5Y Avg
-18.64%
Market Cap
$772.26M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$711.21M
Net Profit Margin
-170055.93%
TTM Avg
-70304.07%
3Y Avg
-35619.60%
5Y Avg
-24164.90%
Market Cap
$710.66M
Net Profit Margin
5.93%
TTM Avg
9.51%
3Y Avg
5.53%
5Y Avg
9.43%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $736.99M | 0.00% | 0.00% | 0.00% | 0.00% |
| Apnimed, Inc. (APMD)vs › | $745.49M | N/A | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $755.18M | -4490.89% | -2245.45% | -2245.45% | -2245.45% |
| Candel Therapeutics, Inc. (CADL)vs › | $724.64M | 0.00% | 0.00% | -3758.80% | -9679.73% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.40M | 0.00% | 0.00% | 0.00% | 0.00% |
| Mesa Laboratories, Inc. (MLAB)vs › | $761.35M | 1.92% | 0.94% | -28.83% | -18.64% |
| Sana Biotechnology, Inc. (SANA)vs › | $772.26M | 0.00% | 0.00% | 0.00% | 0.00% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $711.21M | -170055.93% | -70304.07% | -35619.60% | -24164.90% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $710.66M | 5.93% | 9.51% | 5.53% | 9.43% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $775.12M | -147.38% | -372.93% | -22199.44% | -19748.48% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
